Stockreport

Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018

MOTIF BIO PLC ADRS  (MTFB) 
US:NASDAQ Investor Relations: ir.motifbio.com
PDF NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Positive efficacy and safety highlights from Phase 3 REVIVE-2 trial in ABSSSIPotential to avoid costs related to vanco [Read more]